DOR BioPharma, Inc., owners of the below-identified applications, appoint as their atterneys and/or agents, with full power of substitution and revocation, to prosocute these applications and transact all business in the United States Patent and Trademark Office, all of the registered practitioners identified by Customer Number 32301:

> CATALYST LAW GROUP, APC 9710 Seranton Rd. Suite 170 San Diego, CA 92121:

Serial/Patent		Filed/Issued	Status	Attorney Docket No.
6,096,731	Method for Preventing Tissue Damage Associated with Graft-Host or Host- versus-Graft Disease Following Transplantation	August 1, 2000	Issued	\$105-006-US-CB
10/296-073	Method for Preventing Tissue Damage Associated with Graft-versus-Host or Host-versus-Graft disease following Transplantation	Nevember 22, 2002	Pending	8105-008-WO-US
10/613/788	Method of Long-Term. Treatment of Graft-versus- Host Disease Using Topical Active Corticosteroids		Perding	8105-009-US-CON
	Method of Treating Inflammatory Disorders of the Gestro Intestinal Tract Using Topical Active Corticosteroids	March 15, 2002	Person	8105-010-US
09/928, 890	Method of Treatment of Cancer by Controlling Graft-versus-Leukemia	August 13, 2001	Pending	8105-011-US
	Topical Azathoprine for the Treatment of Oral Autoimmune Diseases	November 4, 1999	Penaing	8105-013-475

Name: Robert N. Bred Ph.D.

Title: Chief Scientific Officer

DATE April 17, 2006